Goodwill and Other Intangible Assets

The Company's goodwill was $25.2 million as of June 30, 2015 and December 31, 2014.

The Company's intangible assets and related accumulated amortization as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands):



		June 30, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(445.1	)	$	554.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,735.9		)	2,164.1		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(356.1		)	443.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	34,290.0		—			34,290.0		43,690.0		—			43,690.0
Patent rights	19 years	669.0		(264.1		)	404.9		669.0		(246.5		)	422.5
Total Intangible Assets		$	40,659.0	$	(2,801.2	)	$	37,857.8	$	50,059.0	$	(2,498.6	)	$	47,560.4

The Company’s in process research and development ("IPR&D") programs were acquired in the Amorcyte Acquisition (CD34 technology) and CSC Acquisition (tumor cell/dendritic cell technology). With regards to the CD34 technology, the Company determined as of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE AMI Phase 2 clinical study, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, that it will not pursue further development of CLBS10 for the acute myocardial infarction indication upon completion of the ongoing PreSERVE AMI Phase 2 clinical study. However, it intends to explore other potential and more commercially viable indications of chronic heart failure and/or critical limb ischemia for its CD34 cell technology platform. These other indications are early stage opportunities, and would require external funding and/or partnerships to proceed to the next step in clinical development. As a result, and given the early stage and funding constraints of these other potential opportunities, the Company determined that IPR&D valued at $9.4 million was fully impaired as of June 30, 2015.

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Cost of revenue	$	74.7	$	78.7	$	153.9	$	158.4
Research and development	31.6		27.6		58.7		54.2
Selling, general and administrative	45.0		45.0		90.0		90.0
Total	$	151.3	$	151.3	$	302.6	$	302.6

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follows (in thousands):



2015	$	302.6
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	35,134.4
Total	$	37,857.8